Eli Frydman

Eli Frydman has a diverse work experience in the healthcare industry. In 2022, they began their role as President - EMEA of Nucleix Ltd., a liquid biopsy company revolutionizing cancer treatment. From 2018 to 2019, they were a Board Member of Carevature Medical Ltd. and a Board Observer of Diagnostic Robotics, Zebra Medical Vision Ltd., BEYEONICS SURGICAL, and Scopio Labs. In 2019, they were also a EU Horizon Europe Jury Member and a Member of 8400 - The Health Network (CC). In 2017, they were a Board Member / Consultant of Precise Bio and in 2016 they were a Managing Director - Healthcare of Aurum Ventures MKI Ltd.

Eli Frydman received their B.Sc in Chemistry & Physics from Tel Aviv University in 1992. Eli then went on to pursue a Ph.D and M.Sc in Chemistry, Materials, and Nanotechnology at the Weizmann Institute of Science, which they completed in 1999. Eli subsequently earned an MBA in Business Administration, Management and Operations from \u00c9cole des Ponts Business School in 2000.